Krystal Biotech (KRYS) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Repligen (RGEN) over the past year, gaining 77.3% versus a gain of 14.6%. Over five years, KRYS leads with a +566.2% price change compared with -37.4% for RGEN. Repligen is the larger company by market cap ($10.40 billion vs $9.69 billion), about 1.1 times the size, while Krystal Biotech is growing revenue faster (+33.9% vs +16.4%).
On valuation, Krystal Biotech trades at a lower forward P/E (35.3x vs 61.8x for Repligen). Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRYS | RGEN |
|---|---|---|
| Share price | $327.30 | $163.84 |
| Market cap | $9.69B | $10.40B |
| 1-day change | +0.84% | -2.02% |
| YTD return | +31.65% | +2.05% |
| 1-year return | +77.34% | +14.59% |
| 5-year return | +566.19% | -37.35% |
| P/E ratio (TTM) | 41.02 | 224.44 |
| Forward P/E | 35.33 | 61.84 |
| EPS (TTM) | $7.98 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $389.13M | $738.26M |
| Revenue growth (YoY) | +33.94% | +16.36% |
| Net income (latest FY) | $204.83M | $48.89M |
| Gross margin | — | 52.32% |
| Operating margin | 41.45% | 7.47% |
| Net margin | 52.64% | 6.62% |
| 52-week high | $382.54 | $198.87 |
| 52-week low | $179.19 | $100.99 |
| Distance from 52-week high | -14.44% | -17.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +19.80% | +18.99% |
| Average volume | 380.77K | 1.17M |
| Shares outstanding | 29.60M | 63.49M |
| Employees | 295 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRYS has outperformed RGEN by 62.8 percentage points over the past year.
- Repligen trades at a higher earnings multiple (224.4x vs 41.0x trailing P/E).
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus 6.6 cents for Repligen.
- Krystal Biotech grew revenue faster in its latest fiscal year (+33.94% vs +16.36%).
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
KRYS vs RGEN FAQ
Which is bigger, Krystal Biotech or Repligen?
Repligen (RGEN) is larger, with a market capitalization of $10.40B compared with $9.69B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, KRYS or RGEN?
KRYS returned +77.34% over the past 12 months, compared with +14.59% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, KRYS or RGEN?
KRYS has the lower trailing P/E at 41.0, versus 224.4 for RGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Krystal Biotech and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.